Detection of a second malignancy in prostate cancer patients by using [18F]Choline PET/CT: a case series
Authors:
- Martina SolliniMSMartina Sollini
- Francesco PasqualettiFPFrancesco Pasqualetti
- Marzio PerriMPMarzio Perri
- Gabriele CoraggioGCGabriele Coraggio
- Paolo CastellucciPCPaolo Castellucci
- Massimo RoncaliMRMassimo Roncali
- Roberto BoniRBRoberto Boni
- Elena LazzeriElena Lazzeri
- Maria GaleandroMGMaria Galeandro
- Fabiola PaiarFPFabiola Paiar
- Annibale VersariAVAnnibale Versari
- Paola Anna ErbaPEPaola Anna Erba
Open Access
- 31 August 2016
- journal article
- case report
- Published by Springer Nature in Cancer Imaging
- Vol. 16 (1) , 1-8
Abstract
The role of radiolabeled choline (Cho) in patients with biochemical recurrence after radical treatment for prostate cancer (PCa) is well established. Its widespread clinical use has prompted the depiction of incidentalomas, unusual sites of metastatic lesions, as well as false positive and negative cases. We reported a series of patients affected by biochemical recurrence of PCa imaged by [18F]Cho positron emission tomography/computed tomography (PET/CT) which resulted suspected for a second malignancy. [18F]Cho PET/CT was performed in patients with biochemical PCa recurrence. From an internal clinical database we identified patients in which PET/CT resulted suspected for a second malignancy. A second malignancy was suspected in presence of “unusual” site of [18F]Cho uptake not consistent with clinical-instrumental history. Histology was used as reference standard for final diagnosis. Seven PCa patients (76 years, 71–84 years) with the suspicion of a second tumor based on [18F]Cho PET/CT findings were identified. Mean value of PSA at the time of [18F]Cho PET/CT was 2,37 ng/mL. The median time between PCa diagnosis and PET/CT was 6 years (range 0–14 years). In two cases history of a second malignancy (lung cancer and cutaneous basocellular carcinoma) was known (diagnosed 12 and 6 years after PCa, respectively). PET/CT identified 13 sites of [18F]Cho uptake (lung = 5, lymph node = 7, bone = 1). Final diagnosis was consistent with lung cancer in 5/7 cases (first diagnosis = 4/5, recurrence = 1/5), colorectal cancer and nodal metastases from melanoma in 1 case each. Although the clinical usefulness of Cho PET/CT for detecting cancer lesions other than prostate origin is known, for those patients who undergo this examination according to indication, the diagnosis of a second tumor has a significant impact on their therapeutic management.Keywords
Funding Information
- Ministero della Salute (IT) (GR-2010-2318367)
This publication has 24 references indexed in Scilit:
- Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2014
- Incidental Diagnosis of Diffuse Large B-Cell Lymphoma by 11C-Choline PET/CT in a Patient With Biochemical Recurrence of Prostate CancerClinical Nuclear Medicine, 2014
- 18F-Choline PET/CT Pitfalls in Image InterpretationClinical Nuclear Medicine, 2014
- Detección de segundos tumores en estudios de la PET/TC con 11C-colina realizados por recurrencia bioquímica de cáncer de próstataRevista Española de Medicina Nuclear e Imagen Molecular, 2014
- Update on positron emission tomography for imaging of prostate cancerInternational Journal of Urology, 2013
- The role of positron emission tomography using carbon-11 and fluorine-18 choline in tumors other than prostate cancer: a systematic reviewAnnals of Nuclear Medicine, 2012
- Salvage Radiotherapy for Patients with PSA Relapse Following Radical Prostatectomy: Issues and ChallengesCancer Research and Treatment, 2010
- 18F-Labeled Positron Emission Tomographic Radiopharmaceuticals in Oncology: An Overview of Radiochemistry and Mechanisms of Tumor LocalizationSeminars in Nuclear Medicine, 2007
- Molecular Causes of the Aberrant Choline Phospholipid Metabolism in Breast CancerCancer Research, 2004
- Prostate cancer ? biology of metastasis and its clinical implicationsWorld Journal of Urology, 1996